While SGLT2 inhibitors did not show a significant effect on stroke reduction, dual SGLT1 and SGLT2 inhibition was associated with a significant decrease in all-cause stroke by 34% (hazard ratio 0.66; 95% CI 0.48–0.91) and ischaemic stroke by 32% (hazard ratio 0.68; 95% CI 0.47 to 0.99) [95]. This evidence concerns the gene SLC5A1 and Stroke.